TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of delayed complications
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of Osteopathic Manipulation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of PTG-300
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain, final percent changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain, final responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Enroll in Any Smoking Cessation Service
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Self-reported Quit Attempt
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of patients
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with Endoleak Type I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Normalized Number of Angioedema Attacks (NNA) Per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Angioedema Quality of Life (AE-QoL) in Treatment Period
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy statistics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity statistics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With HCT Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral Hepatitis B DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Hospital Discharge Disposition
Endpoint domain: Adverse events/effects
Primary endpoint: Change in severity on Clinical Global Impression for Severity (CGI-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Proviral HIV-1 DNA in Total CD4+ T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of exposure to nCPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Blood Volume Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Time-Matched Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Ki67 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profiles of PROCRIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Themes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Low-density-lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of sinusoidal liver injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Device Ease of Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Poor outcome defined by invasive mechanical ventilation or death
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of steroid resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive skin tests and IgE levels ≥30 IU/ml in steroid resistant subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DEX-induced MKP-1 mRNA levels in PBMC or whole blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Normal Blood Pressure Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in global cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in parameters determining renal function and injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: remission rate of gastrointestinal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardiovascular safety assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Central nervous system safety assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ocular safety assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General safety assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of visual acuity (VA) tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of molecules
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PCR of SARS-Cov2 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Evaluation of treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of the incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Economic evaluation
Endpoint domain: Resource use
Primary endpoint: Indication of post-surgical infections
Endpoint domain: Adverse events/effects
Primary endpoint: Limited jaw opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VIPD-Q scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Target-to-background Ratio (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic volume (MV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infarction size (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Moderate and severe COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Return to Sport
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Number of content units expressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of prothesis-patient mismatch (PPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of aortic regurgitation (AR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite Parent and Teacher Conners Rating Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tolerance of extended release mixed amphetamine salts
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postprocedural myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of intention to use a decision aid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Desirability of Outcome Ranking (DOOR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fruit consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Course of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Type of applied anti-cancer therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bladder tissue evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical changes in enteric nervous system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neck posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Simpson-Angus Neurologic Rating Scale (SAS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Suicidality as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events (AEs) by severity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in fentanyl dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of the group intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the group intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SMR for sepsis as a cause of death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of subjects with dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of psychosomatic death
Endpoint domain: Mortality/survival
Primary endpoint: ESSDAI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ESSPRI improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in log10 Viral Load From Baseline to Last Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Viral Load <50 Copies/ml and >=50 Copies/ml at Last Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Absolute CD4 Lymphocytes (CD4+) Cells From Baseline to Last Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative community richness of Clostridia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-progression response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of HostDx Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic performance of HostDx Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients improving clinically and laboratory after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand-Use-at-Home Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: % of patients that are continuously smokefree
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success Scale of the Chronic Pain Values Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Who Experienced Grade 3 or Greater, Treatment Related, Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the concentration of peripheral blood mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Liver Functioning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hamstring muscle stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in eccentric strength (Peak Torque) of the hamstring muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in eccentric strength (Angle of peak torque) of the hamstring muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinically Relevant Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with potentially clinically significant changes in laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with potentially clinically significant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with potentially clinically significant changes in ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Digit Span Total Forward + Backwards
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in menstrual cycle pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Abdominal Fat as measured by Waist Circumference in centimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in glucose tolerance (measured by fasting plasma glucose and 2-hour post prandial plasma glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nasal findings in reactive airway diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in metabolic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in urine volume (production)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in urine composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in serum composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locoregional Recurrence Rate (LRR)
Endpoint domain: Mortality/survival
Primary endpoint: Relief of chronic hip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Discontinuation Rate Due to Zydelig-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clot removal grade for each JETi-treated vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of treated vessel(s) with ≥ 75% venous thrombus reduction via modified Marder score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of JETi-related major adverse events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of sedentary interruptions per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average sedentary time per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local reactogenicity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic reactogenicity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Vital signs abnormalities and/or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory value abnormalities and/or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-LAMP-1 antibody safety assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Reader reliability of screening modalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of moderate/severe side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Attitude and interest toward exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to local progression of brain metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PJK
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Proportion of patients undergoing genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Stages of Recovery Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: diagnosis efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Artery Pulmonary Pressure (sPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiorespiratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in visual acuity and stereo vision measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in ocular tolerability signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline for vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza immunisation uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in CD4+ T cell counts/uL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in CD8+ T cell counts/uL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in CD4/CD8 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The incidence of adverse events (safety and tolerability)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change from baseline in best-corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Occurrence of Sexually Transmitted Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Stroke acute mortality
Endpoint domain: Mortality/survival
Primary endpoint: Reduced Need for Surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Abnormalities in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent excess weight loss (%EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in urinary oxalate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Quality of Life over time
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of Home Parenteral Nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Side effects of doxycycline
Endpoint domain: Adverse events/effects
Primary endpoint: Alteration of genital microecology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) for Active Moiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Plasma Concentration (Cmin) for Active Moiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve to the Last Quantified Concentration (AUClast) for Active Moiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Reported Menorrhagia Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of participants with complications
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal Vitamin D Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial-Fasting FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of Neuropeptide Y, Cortisol and Adrenocorticotropic hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum hepcidin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical score of site and severity of infection and inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of the Wang's Respiratory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first documented improvement in QUALIN score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wolf Motor Function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of first stage of orthodontic finish
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grip and pinch strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median nerve electrophysiologic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes